Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARENA PHARMACEUTICALS INCARNA · Entity 94856 | Executive VP and CFO | March 01, 2020 | March 03, 2020 |
| Apnimed, Inc.APMD · Entity 4910 | Director · Chief Executive Officer | July 30, 2026 | August 03, 2026 |
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director | September 30, 2026 | October 03, 2026 |
| Longboard Pharmaceuticals, Inc.LBPH · Entity 85536 | Director · President and CEO | December 02, 2024 | December 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARENA PHARMACEUTICALS INC
Report date March 01, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.60 · Expires 2027-03-01 | Direct | 70,000 |
Reported balance
After 2020-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-01 · Grant · Acquired 70,000 · Balance 70,000 F1: The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2035-03-06 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Disposition to issuer · Disposed 74,128 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2035-03-06 | Direct | 74,128 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 74,128 · Balance 74,128 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-06-23 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Disposition to issuer · Disposed 1,186,278 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-06-23 | Direct | 1,186,278 |
Reported balance
After 2026-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-03 · Grant · Acquired 1,186,278 · Balance 1,186,278 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 108,916 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Grant · Acquired 108,916 · Balance 108,916 F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Disposition to issuer · Disposed 108,916 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 108,916 |
Reported balance
After 2026-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-03 · Grant · Acquired 108,916 · Balance 108,916 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Avalo Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.33 · Expires 2036-09-30 | Direct | 1,352 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,352 · Balance 1,352 F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1: The options were granted on September 30, 2026, and are 100% vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on September 30, 2026, and are 100% vested.
F2: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.
Longboard Pharmaceuticals, Inc.
Report date December 02, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 1
1 source rowRow 1 · 2024-12-02 · Other · Disposed 363,740 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $60.00 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.12 · Expires 2030-10-26 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-02 · Disposition to issuer · Disposed 255,377 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-12-02 · Disposition to issuer · Disposed 192,783 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.35 · Expires 2033-02-08 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-02 · Disposition to issuer · Disposed 325,850 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.32 · Expires 2034-02-07 | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-12-02 · Disposition to issuer · Disposed 332,134 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-12-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-12-02 · Disposition to issuer · Disposed 22,000 · Balance 0 F4: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F5: The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an "involuntary termination" (as defined in such officer's respective employment agreement with the Issuer). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $60.00 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration.
F3: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes.
F4: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time.
F5: The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an "involuntary termination" (as defined in such officer's respective employment agreement with the Issuer).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,352 | $12.29 Strike: $15.33 | $16,616.08 |
DisclosureSEC source: 0001677036-26-000009 · form4-10022026_041018.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,352 Underlying: Common Stock · 1,352 shares Expires 2036-09-30 F2 · price: The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. F1 · derivative.exercise_date: The options were granted on September 30, 2026, and are 100% vested. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 108,916 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 7 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,916 Underlying: Common Stock · 108,916 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 108,916 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 6 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 108,916 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 1,186,278 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 4 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,186,278 Underlying: Common Stock · 1,186,278 shares Expires 2036-06-23 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,186,278 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,186,278 shares Expires 2036-06-23 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 74,128 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,128 Underlying: Common Stock · 74,128 shares Expires 2035-03-06 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 74,128 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 74,128 shares Expires 2035-03-06 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 108,916 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330505 · ownership.xml · derivative · entry 5 Lind Kevin Robert · CIK 0001677036 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,916 Underlying: Class A Common Stock · 108,916 shares Expires 2036-07-29 F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,105 | $15.04 Strike: $18.48 | $16,619.20 |
DisclosureSEC source: 0001677036-26-000006 · form4-07022026_040719.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires 2036-06-30 F1 · derivative.exercise_date: The options were granted on June 30, 2026, and are 100% vested. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 20,100 | $0.00 Strike: $13.96 | $0.00 |
DisclosureSEC source: 0001677036-26-000004 · form4-06042026_040609.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2036-06-02 F1 · derivative.exercise_date: The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 1,370 | $12.13 Strike: $14.93 | $16,618.10 |
DisclosureSEC source: 0001677036-26-000002 · form4-04012026_040408.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,370 Underlying: Common Stock · 1,370 shares Expires 2036-03-31 F1 · derivative.exercise_date: The options were granted on March 31, 2026, and are 100% vested. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 848 | $14.74 Strike: $18.16 | $12,499.52 |
DisclosureSEC source: 0001470831-26-000007 · form4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848 Underlying: Common Stock · 848 shares Expires 2035-12-31 F1 · derivative.exercise_date: The options were granted on December 31, 2025, and are 100% vested. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:23 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,200 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001677036-25-000004 · primary_doc.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,200 Underlying: Common Stock · 40,200 shares Expires 2035-10-01 F1 · derivative.exercise_date: The stock option vests in three substantially equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerRestricted Stock Unit · Derivative | 22,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · derivative · entry 6 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,000 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time. F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F4 · price: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time. F5 · price: The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an "involuntary termination" (as defined in such officer's respective employment agreement with the Issuer). F4 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time. F5 · derivative.exercise_date: The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an "involuntary termination" (as defined in such officer's respective employment agreement with the Issuer). F4 · derivative.expiration_date: At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the "Retention RSUs"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time. F5 · derivative.expiration_date: The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an "involuntary termination" (as defined in such officer's respective employment agreement with the Issuer). Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 332,134 | Not disclosed Strike: $19.32 | Not disclosed |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · derivative · entry 5 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332,134 shares Expires 2034-02-07 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 325,850 | Not disclosed Strike: $4.35 | Not disclosed |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · derivative · entry 4 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 325,850 shares Expires 2033-02-08 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 192,783 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192,783 shares Expires 2032-02-08 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 255,377 | Not disclosed Strike: $3.12 | Not disclosed |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · derivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255,377 shares Expires 2030-10-26 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F3 · price: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. F3 · derivative.exercise_date: At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes. Read SEC document |
| December 02, 2024 Filed Dec 3, 2024 00:17 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | OtherCommon Stock | 363,740 | $60.00 | $21,824,400.00 |
DisclosureSEC source: 0001415889-24-028021 · form4-12032024_121211.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the "Issuer"), H. Lundbeck A/S ("Parent"), Lundbeck LLC ("Payor"), and Langkawi Corporation ("Purchaser"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $60.00 per Share, in cash, without interest, subject to any applicable withholding of taxes (the "Merger Consideration"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the "Effective Time"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 01:48 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,808 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0000950170-24-126650 · ownership.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,377 Underlying: Common Stock · 12,808 shares Expires 2030-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a cash exercise of vested stock options without a subsequent sale of the underlying shares of common stock. F3 · derivative.exercise_date: The shares subject to the stock option vested and became exercisable in 24 equal monthly installments commencing November 27, 2022. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 01:48 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GiftCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-126650 · ownership.xml · nonDerivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,740 F2 · kind: Represents shares of common stock gifted to a donor-advised trust. Read SEC document |
| November 13, 2024 Filed Nov 14, 2024 01:48 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionCommon Stock | 12,808 | $3.12 | $40,001.95 |
DisclosureSEC source: 0000950170-24-126650 · ownership.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents a cash exercise of vested stock options without a subsequent sale of the underlying shares of common stock. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:38 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantRetention Restricted Stock Units · Derivative | 22,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118308 · ownership.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Voting Common Stock · 22,000 shares Expires not disclosed F1 · derivative.exercise_date: The retention restricted stock units ("Retention RSUs") vest in full on the earlier of October 25, 2025, or the date of the Reporting Person's Involuntary Termination (as defined in the Reporting Person's employment agreement) (such earlier date, the "Vesting Date"). The shares underlying the Retention RSUs will be issued upon vesting and release of the Retention RSUs. If the acquisition of the Issuer pursuant to the Agreement and Plan of Merger attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on October 15, 2024 (the "Merger Agreement") is completed prior to the Vesting Date, then, as of and following the Effective Time (as defined in the Merger Agreement), the Retention RSUs shall be settled via payment of an amount in cash, without interest, equal to the product of the Merger Consideration (as defined in the Merger Agreement) multiplied by the number of Retention RSUs, with such amount payable to the Reporting Person on the Vesting Date. F1 · derivative.expiration_date: The retention restricted stock units ("Retention RSUs") vest in full on the earlier of October 25, 2025, or the date of the Reporting Person's Involuntary Termination (as defined in the Reporting Person's employment agreement) (such earlier date, the "Vesting Date"). The shares underlying the Retention RSUs will be issued upon vesting and release of the Retention RSUs. If the acquisition of the Issuer pursuant to the Agreement and Plan of Merger attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on October 15, 2024 (the "Merger Agreement") is completed prior to the Vesting Date, then, as of and following the Effective Time (as defined in the Merger Agreement), the Retention RSUs shall be settled via payment of an amount in cash, without interest, equal to the product of the Merger Consideration (as defined in the Merger Agreement) multiplied by the number of Retention RSUs, with such amount payable to the Reporting Person on the Vesting Date. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 22:03 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,217 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000950170-24-096499 · ownership.xml · derivative · entry 4 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,783 Underlying: Common Stock · 2,217 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 22:03 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionStock Option (Right to Buy) · Derivative | 80,265 | $0.00 Strike: $3.12 | $0.00 |
DisclosureSEC source: 0000950170-24-096499 · ownership.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,185 Underlying: Common Stock · 80,265 shares Expires 2030-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 24 equal monthly installments commencing November 27, 2022. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 22:03 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionCommon Stock | 2,217 | $4.20 | $9,311.40 |
DisclosureSEC source: 0000950170-24-096499 · ownership.xml · nonDerivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 22:03 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | Exercise / conversionCommon Stock | 80,265 | $3.12 | $250,683.65 |
DisclosureSEC source: 0000950170-24-096499 · ownership.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:06 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 332,134 | $0.00 Strike: $19.32 | $0.00 |
DisclosureSEC source: 0001209191-24-003025 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,134 Underlying: Voting common stock · 332,134 shares Expires 2034-02-07 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 8, 2024. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 21:27 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 325,850 | $0.00 Strike: $4.35 | $0.00 |
DisclosureSEC source: 0001209191-23-008384 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,850 Underlying: Voting common stock · 325,850 shares Expires 2033-02-08 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 21:48 UTC | Longboard Pharmaceuticals, Inc. LBPH · Entity 85536 | GrantStock Option (Right to Buy) · Derivative | 195,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-22-008911 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Voting common stock · 195,000 shares Expires 2032-02-08 F1 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2022. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 18:10 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $44.60 | $0.00 |
DisclosureSEC source: 0001209191-20-015576 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-03-01 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $35.60 | $0.00 |
DisclosureSEC source: 0001209191-20-009834 · doc4.xml · derivative · entry 5 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,000 Underlying: Common Stock · 2,000 shares Expires 2025-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $19.40 | $0.00 |
DisclosureSEC source: 0001209191-20-009834 · doc4.xml · derivative · entry 4 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 2,500 shares Expires 2023-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on June 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | SaleCommon Stock | 4,500 | $55.00 | $247,500.00 |
DisclosureSEC source: 0001209191-20-009834 · doc4.xml · nonDerivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,457 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionCommon Stock | 2,000 | $35.60 | $71,200.00 |
DisclosureSEC source: 0001209191-20-009834 · doc4.xml · nonDerivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 19:40 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionCommon Stock | 2,500 | $19.40 | $48,500.00 |
DisclosureSEC source: 0001209191-20-009834 · doc4.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionPerformance Restricted Stock Unit · Derivative | 6,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053333 · doc4.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 6,300 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. F1 · shares: On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. F1 · derivative.exercise_date: On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. F4 · derivative.underlying_shares: The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 18,900 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. F1 · balance_after: On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Tax withholdingCommon Stock | 3,091 | $47.32 | $146,266.12 |
DisclosureSEC source: 0001209191-19-053333 · doc4.xml · nonDerivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,457 F3 · shares: Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | Exercise / conversionCommon Stock | 6,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053333 · doc4.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met. F2 · balance_after: Includes 62 shares acquired on March 31, 2017, and 62 shares acquired on June 30, 2017, pursuant to the 2009 Arena Employee Stock Purchase Plan. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:00 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Performance Restricted Stock Unit · Derivative | 12,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002950 · doc4.xml · derivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 Underlying: Common Stock · 12,600 shares Expires 2022-01-03 F2 · derivative.exercise_price: Each Employee Performance Restricted Stock Unit ("PRSU") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019 through January 3, 2022 (the "Performance Period") and satisfaction of a continuing service requirement. F3 · shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · derivative.exercise_date: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · derivative.underlying_shares: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. F3 · balance_after: The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:00 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $40.94 | $0.00 |
DisclosureSEC source: 0001209191-19-002950 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-01-04 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on January 4, 2020, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| January 19, 2018 Filed Jan 22, 2018 17:28 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $35.60 | $0.00 |
DisclosureSEC source: 0001209191-18-004771 · doc4.xml · derivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2025-01-19 F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 20:21 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 1,044,750 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-17-010903 · doc4.xml · derivative · entry 3 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044,750 Underlying: Common Stock · 1,044,750 shares Expires 2024-02-13 F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| December 30, 2016 Filed Feb 14, 2017 20:21 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 625 | $1.21 | $756.25 |
DisclosureSEC source: 0001209191-17-010903 · doc4.xml · nonDerivative · entry 2 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 F1 · kind: These shares were acquired pursuant to the 2009 Arena Employee Stock Purchase Plan. Read SEC document |
| September 30, 2016 Filed Feb 14, 2017 20:21 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | OtherCommon Stock | 625 | $1.41 | $881.25 |
DisclosureSEC source: 0001209191-17-010903 · doc4.xml · nonDerivative · entry 1 Lind Kevin Robert · CIK 0001677036 · Executive VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 F1 · kind: These shares were acquired pursuant to the 2009 Arena Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.